A Phase 1b Viral Kinetic Study of VX-950 [telaprevir] and Peginterferon in Hepatitis C

Trial Profile

A Phase 1b Viral Kinetic Study of VX-950 [telaprevir] and Peginterferon in Hepatitis C

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Nov 2005

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa-2a
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 25 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top